30 ML sodium chloride 234 MG/ML Injection — RxCUI 1807571
RxNorm drug concept · Semantic clinical drug
RxCUI 1807571
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1807571
Official name30 ML sodium chloride 234 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known as30 ML NaCl 234 MG/ML Injection; sodium chloride 23.4 % in 30 ML Injection; sodium chloride 120 MEQ per 30 ML Injection; sodium chloride 23.4 % per 30 ML Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)3,487 prescriptions · 17 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Sodium Chloride: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It depends on the product. IV forms replace fluid and salt, while injection diluents dissolve other drugs. Other forms are used for rinsing, nasal congestion and nasal care, or to...
- Follow the directions on your product. Many are used as often as needed by adults and children 4 and over. Do not share the bottle, because that can spread infection.
- Some people get fever, irritation or infection at the IV site, or too much fluid in the body. Tell your nurse right away if the IV site hurts or looks red.
- What side effects should I expect with IV sodium chloride?
🕸️ Concept Web — How 30 ML sodium chloride 234 MG/ML Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
30 ML sodium chloride 234 MG/ML Injection
RxCUI 1807571 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sodium chloride
9863IN
-
Sodium chloride
-
Dose forms 4
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sodium chloride Injection
1807545SCDF -
Sodium chloride Injectable Product
1159317SCDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Sodium chloride Injection
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sodium chloride 234 MG/ML
1807564SCDC
-
Sodium chloride 234 MG/ML
Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sodium chloride 234 MG/ML
SCDC · 1807564 -
Sodium chloride Injection
SCDF · 1807545 -
Sodium chloride Injectable Product
SCDG · 1159317
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 1807571 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00404-9978-30 | 1 VIAL in 1 BAG (0404-9978-30) / 30 mL in 1 VIAL | SODIUM CHLORIDE | Henry Schein, Inc. | 2022-01-12 |
| 63323-0093-30 | 25 VIAL, PLASTIC in 1 TRAY (63323-093-30) / 30 mL in 1 VIAL... | Sodium Chloride | Fresenius Kabi USA, LLC | 2021-04-28 |
Observed labelers:
Fresenius Kabi USA, LLC (1) ·
Henry Schein, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.